A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
(POPLAR Trial)

Recruiting in Palo Alto (17 mi)

+40 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: AnaptysBio, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)

Research Team

Bruce Randazzo, MD

Principal Investigator

AnaptysBio, Inc.

Eligibility Criteria

Inclusion Criteria

Clinically confirmed diagnosis of PPP

Disease duration of at least 6 months prior to screening

Present with active pustules on palms or/and soles at screening

Treatment Details

Interventions

Imsidolimab (Monoclonal Antibodies)

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: imsidolimabExperimental Treatment1 Intervention

Participants will receive 200 mg imsidolimab by subcutaneous injection on Day 1 followed by monthly doses of 100 mg imsidolimab by subcutaneous injection on Days 29, 57, and 85.

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive placebo administered by subcutaneous injection on Day 1 followed by monthly doses of placebo by subcutaneous injection on Days 29, 57, and 85.